Events - Ocugen
Maybe your like
- Home
- Events
Upcoming Events
03/04/2026Ocugen, Inc. Q4 and Full Year 2025 Financial Results and Business Highlights
Past Events
01/15/202644th Annual J.P. Morgan Healthcare Conference
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Oppenheimer Movers in Rare Disease Summit
Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
Ocugen, Inc. Third Quarter 2025 Financial Results and Recent Business Highlights
Chardan’s 9th Annual Genetic Medicines Conference
Biotech on Tap
H.C. Wainwright 27th Annual Global Investment Conference
Ocugen, Inc. Second Quarter 2025 Financial Results and Recent Business Highlights
Chardan Virtual Ophthalmology Summit Series: Rare Ophthalmic Diseases
2025 BIO Presentation
Noble Capital Markets’ Emerging Growth Virtual Equity Conference
Ocugen, Inc. First Quarter 2025 Financial Results and Recent Business Highlights
Chardan's Trending Issues in Drug Development Conference Series, Topic: Data & Regulatory Catalysts – Navigating an Evolving Landscape
2025 Cell & Gene Meeting
Ocugen, Inc. Q4 and Full Year 2024 Financial Results and Business Highlights
Oppenheimer Movers in Rare Disease Summit
Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
Clinical Showcase
Ocugen’s website uses cookies to enhance site navigation and analyze site usage. By clicking “Accept Cookies” or continuing to use this website, you are agreeing to our use of cookies. Click here to see our Cookie Policy
Accept CookiesTag » When Will Ocugen Get Fda Approval
-
Ocugen COVID Shot Will Have To Wait For US Market As FDA Slaps Clinical Hold On Phase 3 Trial
-
FDA Lifts Hold On Ocugen's COVID-19 Vaccine Trial. But Is It Too Late For The Shot?
-
FDA Slaps Another Hold On Ocugen, Bharat's COVID Vaccine After WHO Flags Manufacturing Problems
-
Ocugen: Latest News & Videos, Photos About Ocugen | The Economic Times - Page 1
-
Ocugen Inc. - Clinical-Stage Biotechnology
-
Ocugen: FDA Lifts Hold As Shares Sink - Worth Staying The Course? (NASDAQ:OCGN)